Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis

Respirol Case Rep. 2018 Sep 14;6(8):e00363. doi: 10.1002/rcr2.363. eCollection 2018 Nov.

Abstract

A 76-year-old man with a past history of acute exacerbation (AE) and idiopathic pulmonary fibrosis (IPF) was treated with nintedanib because of decline in his forced vital capacity over time. A new small nodular lesion was visible on a computed tomography scan of the chest before initiation of nintedanib. Disease progression in IPF and change in size of the nodular lesion were not detected during administration of nintedanib. Nine months after starting nintedanib, the patient was diagnosed with acute gangrenous appendicitis, and nintedanib treatment was discontinued. The nodular lesion increased in size four months after the cessation of nintedanib. The nodular lesion was diagnosed as squamous cell carcinoma. In this case, nintedanib inhibited the disease progression of IPF and lung cancer simultaneously. Nintedanib may play an important role in the treatment of IPF-associated lung cancer.

Keywords: Idiopathic pulmonary fibrosis; nintedanib; squamous cell carcinoma.

Publication types

  • Case Reports